HSCS (HeartSciences) ROCE %: -199.48% (As of Jan. 2026)


HSCS HeartSciences Inc HSCS
41 GF Score
Price $2.90
GF Value $2.61
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is HeartSciences ROCE %?

HeartSciences HSCS -1.18% 41 ROCE % is -199.48% as of Jan. 2026. GuruFocus rates HSCS with a GF Score™ of 41/100 and a GF Value™ of $2.61 (Modestly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. HeartSciences's annualized ROCE % for the quarter that ended in Jan. 2026 was -199.48%.

HeartSciences  (NAS:HSCS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

HeartSciences ROCE % Related Terms

HeartSciences ROCE % Historical Data

* Premium members only.

The historical data trend for HeartSciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeartSciences ROCE % Chart

HeartSciences Annual Data
Trend Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
ROCE %
Get a 7-Day Free Trial -285.19 0.00 -16,975.00 -135.82 -199.85

HeartSciences Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -285.39 -576.86 -379.71 -211.00 -199.48
HSCS
41GF Score
HeartSciences Inc HSCS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HeartSciences ROCE % Calculation

HeartSciences's annualized ROCE % for the fiscal year that ended in Apr. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=-8.265/( ( (9.503 - 1.752) + (4.223 - 3.703) )/ 2 )
=-8.265/( (7.751+0.52)/ 2 )
=-8.265/4.1355
=-199.85 %

HeartSciences's ROCE % of for the quarter that ended in Jan. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=-7.696/( ( (5.996 - 1.566) + (7.555 - 4.269) )/ 2 )
=-7.696/( ( 4.43 + 3.286 )/ 2 )
=-7.696/3.858
=-199.48 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -199.48% mean?
HeartSciences (HSCS) has a ROCE % of -199.48% as of Jan. 2026.
Is HeartSciences' ROCE % too high?
HeartSciences' current ROCE % is -199.48%. Overall, HeartSciences has a GF Score™ of 41/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HeartSciences' ROCE % compare to FEED and ITOC?
HeartSciences' ROCE % of -199.48% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeartSciences's current ROCE % is -199.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeartSciences stock overvalued right now?
Based on GuruFocus' analysis, HeartSciences (HSCS) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.61, compared to a current price of $2.90 — trading 11.1% above its estimated fair value. The current ROCE % is -199.48%. HeartSciences' overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For HeartSciences (HSCS), the current ROCE % is -199.48% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HeartSciences (HSCS) Overvalued in 2026?

Based on GuruFocus' analysis, HeartSciences stock appears to be overvalued. The current stock price of $2.90 is trading 11.1% above its estimated GF Value™ of $2.61. GuruFocus considers HeartSciences to be Modestly Overvalued.

Key valuation signals for HSCS:

  • ROCE %: -199.48%
  • GF Value™: $2.61 vs. price of $2.90 (11.1% above fair value)
  • GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the HSCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HeartSciences Business Description

Address 550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
41GF Score

Get the complete analysis for HSCS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.90
Price
$2.61
GF Value